Skip to main content
SpringerLink
Log in

Reproductive Issues in Breast Cancer

  • Chapter
  • First Online:
Breast Disease

  • 846 Accesses

Abstract

In this chapter, our aim is to present associations between the risk of developing breast cancer and reproductive issues, breast cancer treatment and fetal effects during pregnancy, and finally evidence regarding the effect of breast cancer treatments on fertility and potential fertility preservation methods. Strong evidence regarding reproductive risks exists for hormone (estrogen and/or progesterone) receptor-positive (HR+) breast cancers. Specifically, plausible data in the literature suggest significant associations between HR-positive breast cancers and nulliparity, current hormone use, and age at first birth. If breast cancer is detected during pregnancy, termination of the pregnancy does not necessarily improve the cancer prognosis. Breast cancer during pregnancy must be managed with a multidisciplinary approach that should follow standard protocols for nonpregnant patients as much as possible while considering the safety of the fetus. Various assisted reproductive technology (ART) approaches are available for breast cancer patients who wish to preserve fertility after cancer treatment. These approaches can be utilized before or after the initiation of adjuvant breast cancer treatment. Hence, adequate counseling should be provided to premenopausal breast cancer patients prior to cancer treatment. If the patient wishes to preserve her fertility, her chances must be optimized by providing the most suitable ART treatment via a multidisciplinary approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. SEER stat fact sheets: female breast cancer. Available from: URL: http://seer.cancer.gov/statfacts/html/breast.html. Accessed 15 Jan 2017.

  2. Bao PP, Shu XO, Gao YT, Zheng Y, Cai H, Deming SL, et al. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. Am J Epidemiol. 2011;174:661–71.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Chung S, Park SK, Sung H, Song N, Han W, Noh DY, et al. Association between chronological change of reproductive factors and breast cancer risk defined by hormone receptor status: results from the Seoul Breast Cancer Study. Breast Cancer Res Treat. 2013;140:557–65.

    Article  CAS  PubMed  Google Scholar 

  4. Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, et al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. 2011;130:587–97.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age. Breast Cancer Res Treat. 2013;137:579–87.

    Article  CAS  PubMed  Google Scholar 

  6. Li CI, Malone KE, Daling JR, Potter JD, Bernstein L, Marchbanks PA, et al. Timing of menarche and first full-term birth in relation to breast cancer risk. Am J Epidemiol. 2008;167:230–9.

    Article  PubMed  Google Scholar 

  7. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res BCR. 2006;8:R43.

    Article  PubMed  CAS  Google Scholar 

  8. Ma H, Henderson KD, Sullivan-Halley J, Duan L, Marshall SF, Ursin G, et al. Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. Breast Cancer Res BCR. 2010;12:R35.

    Article  PubMed  Google Scholar 

  9. Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L. Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2011;20:1883–91.

    Article  CAS  Google Scholar 

  10. Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control CCC. 2011;22:399–405.

    Article  PubMed  Google Scholar 

  11. Ritte R, Tikk K, Lukanova A, Tjonneland A, Olsen A, Overvad K, et al. Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study. BMC Cancer. 2013;13:584.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol. 2009;169:1251–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control CCC. 2009;20:1071–82.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Warner ET, Colditz GA, Palmer JR, Partridge AH, Rosner BA, Tamimi RM. Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40? Breast Cancer Res Treat. 2013;142:165–75.

    Article  CAS  PubMed  Google Scholar 

  15. Warner ET, Tamimi RM, Boggs DA, Rosner B, Rosenberg L, Colditz GA, et al. Estrogen receptor positive tumors: do reproductive factors explain differences in incidence between black and white women? Cancer Causes Control CCC. 2013;24:731–9.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Xing P, Li J, Jin F. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol. 2010;27:926–31.

    Article  PubMed  Google Scholar 

  17. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103:250–63.

    Article  PubMed  Google Scholar 

  18. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2007;16:439–43.

    Article  CAS  Google Scholar 

  19. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109:123–39.

    Article  PubMed  Google Scholar 

  20. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011;103:470–7.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Islam T, Matsuo K, Ito H, Hosono S, Watanabe M, Iwata H, et al. Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23:2435–41.

    Article  CAS  Google Scholar 

  22. Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;131:159–67.

    Article  CAS  PubMed  Google Scholar 

  23. Ritte R, Lukanova A, Berrino F, Dossus L, Tjonneland A, Olsen A, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res BCR. 2012;14:R76.

    Article  PubMed  Google Scholar 

  24. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2009;18:1157–66.

    Article  Google Scholar 

  25. Burkman RT, Tang MT, Malone KE, Marchbanks PA, McDonald JA, Folger SG, et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women’s Contraceptive and Reproductive Experiences Study. Fertil Steril. 2003;79:844–51.

    Article  PubMed  Google Scholar 

  26. Kallen B, Finnstrom O, Lindam A, Nilsson E, Nygren KG, Olausson PO. Malignancies among women who gave birth after in vitro fertilization. Hum Reprod. 2011;26:253–8.

    Article  CAS  PubMed  Google Scholar 

  27. Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2007;16:1400–7.

    Article  CAS  Google Scholar 

  28. Zreik TG, Mazloom A, Chen Y, Vannucci M, Pinnix CC, Fulton S, et al. Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat. 2010;124:13–26.

    Article  PubMed  Google Scholar 

  29. Amant F, Deckers S, Van Calsteren K, Loibl S, Halaska M, Brepoels L, et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer. 2010;46:3158–68.

    Article  PubMed  Google Scholar 

  30. Sorosky JI, Scott-Conner CE. Breast disease complicating pregnancy. Obstet Gynecol Clin N Am. 1998;25:353–63.

    Article  CAS  Google Scholar 

  31. Ives A, Musiello T, Saunders C. The experience of pregnancy and early motherhood in women diagnosed with gestational breast cancer. Psychooncology. 2012;21:754–61.

    Article  CAS  PubMed  Google Scholar 

  32. Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J. 2010;16:76–82.

    Article  PubMed  Google Scholar 

  33. Nugent P, O’Connell TX. Breast cancer and pregnancy. Arch Surg. 1985;120:1221–4.

    Article  CAS  PubMed  Google Scholar 

  34. Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Burke B, Sutcliffe SB, et al. Maternal and fetal outcome after breast cancer in pregnancy. Am J Obstet Gynecol. 1992;166:781–7.

    Article  CAS  PubMed  Google Scholar 

  35. Cohen-Kerem R, Railton C, Oren D, Lishner M, Koren G. Pregnancy outcome following non-obstetric surgical intervention. Am J Surg. 2005;190:467–73.

    Article  PubMed  Google Scholar 

  36. Moran BJ, Yano H, Al Zahir N, Farquharson M. Conflicting priorities in surgical intervention for cancer in pregnancy. Lancet Oncol. 2007;8:536–44.

    Article  PubMed  Google Scholar 

  37. Ni Mhuireachtaigh R, O’Gorman DA. Anesthesia in pregnant patients for nonobstetric surgery. J Clin Anesth. 2006;18:60–6.

    Article  CAS  PubMed  Google Scholar 

  38. Dominici LS, Kuerer HM, Babiera G, Hahn KM, Perkins G, Middleton L, et al. Wound complications from surgery in pregnancy-associated breast cancer (PABC). Breast Dis. 2010;31:1–5.

    Article  PubMed  Google Scholar 

  39. Gumus N. Severe influence of early pregnancy on newly reconstructed breast. Breast. 2008;17:429–31.

    Article  PubMed  Google Scholar 

  40. Gentilini O, Cremonesi M, Toesca A, Colombo N, Peccatori F, Sironi R, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging. 2010;37:78–83.

    Article  PubMed  Google Scholar 

  41. Gentilini O, Cremonesi M, Trifiro G, Ferrari M, Baio SM, Caracciolo M, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2004;15:1348–51.

    Article  CAS  Google Scholar 

  42. Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol. 2005;6:328–33.

    Article  PubMed  Google Scholar 

  43. Keleher A, Wendt R 3rd, Delpassand E, Stachowiak AM, Kuerer HM. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004;10:492–5.

    Article  PubMed  Google Scholar 

  44. Ellner SJ, Hoh CK, Vera DR, Darrah DD, Schulteis G, Wallace AM. Dose-dependent biodistribution of [(99m)Tc]DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping. Nucl Med Biol. 2003;30:805–10.

    Article  CAS  PubMed  Google Scholar 

  45. Khera SY, Kiluk JV, Hasson DM, Meade TL, Meyers MP, Dupont EL, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. 2008;14:250–4.

    Article  PubMed  Google Scholar 

  46. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5:283–91.

    Article  CAS  PubMed  Google Scholar 

  47. Peccatori FA, Azim HA Jr, Scarfone G, Gadducci A, Bonazzi C, Gentilini O, et al. Weekly epirubicin in the treatment of gestational breast cancer (GBC). Breast Cancer Res Treat. 2009;115:591–4.

    Article  CAS  PubMed  Google Scholar 

  48. Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010;102:1845–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17:855–61.

    Article  CAS  Google Scholar 

  50. Ebert U, Loffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther. 1997;74:207–20.

    CAS  PubMed  Google Scholar 

  51. Garcia-Manero M, Royo MP, Espinos J, Pina L, Alcazar JL, Lopez G. Pregnancy associated breast cancer. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2009;35:215–8.

    CAS  Google Scholar 

  52. Giacalone PL, Laffargue F, Benos P. Chemotherapy for breast carcinoma during pregnancy: a French national survey. Cancer. 1999;86:2266–72.

    Article  CAS  PubMed  Google Scholar 

  53. Hahn KM, Johnson PH, Gordon N, Kuerer H, Middleton L, Ramirez M, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006;107:1219–26.

    Article  PubMed  Google Scholar 

  54. Mir O, Berveiller P, Goffinet F, Treluyer JM, Serreau R, Goldwasser F, et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2010;21:425–6.

    Article  CAS  Google Scholar 

  55. Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:4192–7.

    Article  Google Scholar 

  56. Van Calsteren K, Heyns L, De Smet F, Van Eycken L, Gziri MM, Van Gemert W, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:683–9.

    Article  Google Scholar 

  57. Aviles A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma. 2001;2:173–7.

    Article  CAS  PubMed  Google Scholar 

  58. Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;13:256–64.

    Article  CAS  PubMed  Google Scholar 

  59. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679–91.

    Article  CAS  PubMed  Google Scholar 

  60. Minsker DH, Manson JM, Peter CP. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol. 1993;121:217–23.

    Article  CAS  PubMed  Google Scholar 

  61. Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2009;44:428–30.

    Article  CAS  PubMed  Google Scholar 

  62. Isaacs RJ, Hunter W, Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy – case report and literature review. Gynecol Oncol. 2001;80:405–8.

    Article  CAS  PubMed  Google Scholar 

  63. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5:953–62.

    CAS  PubMed  Google Scholar 

  64. Azim HA Jr, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol. 2010;6:821–6.

    Article  PubMed  Google Scholar 

  65. Arriagada R, Le MG, Contesso G, Guinebretiere JM, Rochard F, Spielmann M. Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2002;13:1404–13.

    Article  CAS  Google Scholar 

  66. Emens LA, Davidson NE. Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9:486S–94.

    CAS  Google Scholar 

  67. Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. Endocrinol Metab Clin N Am. 1998;27:989–1006.

    Article  CAS  Google Scholar 

  68. Malamos NA, Stathopoulos GP, Keramopoulos A, Papadiamantis J, Vassilaros S. Pregnancy and offspring after the appearance of breast cancer. Oncology. 1996;53:471–5.

    Article  CAS  PubMed  Google Scholar 

  69. Oktem O, Oktay K. Fertility preservation for breast cancer patients. Semin Reprod Med. 2009;27:486–92.

    Article  PubMed  Google Scholar 

  70. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:2500–10.

    Article  Google Scholar 

  71. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306:269–76.

    PubMed  Google Scholar 

  72. McLaren JF, Bates GW. Fertility preservation in women of reproductive age with cancer. Am J Obstet Gynecol. 2012;207:455–62.

    Article  PubMed  Google Scholar 

  73. Barcroft J, Dayoub N, Thong KJ. Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation. J Assist Reprod Genet. 2013;30:1407–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Chian RC, Uzelac PS, Nargund G. In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril. 2013;99:1173–81.

    Article  CAS  PubMed  Google Scholar 

  75. Park CW, Lee SH, Yang KM, Lee IH, Lim KT, Lee KH, Kim TJ. Cryopreservation of in vitro matured oocytes after ex vivo oocyte retrieval from gynecologic cancer patients undergoing radical surgery. Clin Exp Reprod Med. 2016;43:119–25. [PMID: 27358831]. https://doi.org/10.5653/cerm.2016.43.2.119.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Lee JA, Barritt J, Moschini RM, Slifkin RE, Copperman AB. Optimizing human oocyte cryopreservation for fertility preservation patients: should we mature then freeze or freeze then mature? Fertil Steril. 2013;99:1356–62. [PMID: 23266213]. https://doi.org/10.1016/j.fertnstert.2012.11.042.

    Article  PubMed  Google Scholar 

  77. Chian RC, Huang JY, Gilbert L, Son WY, Holzer H, Cui SJ, Buckett WM, Tulandi T, Tan SL. Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes. Fertil Steril. 2009;91:2391–8. [PMID: 18579139]. https://doi.org/10.1016/j.fertnstert.2008.04.014.

    Article  PubMed  Google Scholar 

  78. Dolmans MM, Luyckx V, Donnez J, Andaersen CY, Greve T. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril. 2013;99:1514–22.

    Article  PubMed  Google Scholar 

  79. Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Live birth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364:1405–10.

    Article  CAS  PubMed  Google Scholar 

  80. Oktay K, Bedoschi G, Pacheco F, Turan V, Emirdar V. First pregnancies, live birth, and in vitro fertilization outcomes after transplantation of frozenbanked ovarian tissue with a human extracellular matrix scaffold using robotassisted minimally invasive surgery. Am J Obstet Gynecol. 2016;214:94.e1–9. [PMID: 26601616]. https://doi.org/10.1016/j.ajog.2015.10.001.

    Article  Google Scholar 

  81. Donnez J, Dolmans MM, Pellicer A, Diaz-Garcia C, Sanchez Serrano M, Schmidt KT, et al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertil Steril. 2013;99:1503–13.

    Article  PubMed  Google Scholar 

  82. el Hussein E, Tan SL. Successful in vitro fertilization and embryo transfer after treatment of invasive carcinoma of the breast. Fertil Steril. 1992;58:194–6.

    Article  PubMed  Google Scholar 

  83. Garcia-Velasco JA, Domingo J, Cobo A, Martinez M, Carmona L, Pellicer A. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil Steril. 2013;99:1994–9.

    Article  PubMed  Google Scholar 

  84. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol. 2001;97:855–66.

    CAS  PubMed  Google Scholar 

  85. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18:90–5.

    Article  CAS  PubMed  Google Scholar 

  86. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:4347–53.

    Article  CAS  Google Scholar 

  87. Oktay K, Buyuk E, Rodriguez-Wallberg KA, Sahin G. In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. Reprod Biomed Online. 2010;20:634–8.

    Article  CAS  PubMed  Google Scholar 

  88. Oktay K, Oktem O. Ovarian cryopreservation and transplantation for fertility preservation for medical indications: report of an ongoing experience. Fertil Steril. 2010;93:762–8.

    Article  PubMed  Google Scholar 

  89. Prest SJ, May FE, Westley BR. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J Off Publ Fed Am Soc Exp Biol. 2002;16:592–4.

    CAS  Google Scholar 

  90. Taylan E, Oktay KH. Current state and controversies in fertility preservation in women with breast cancer. World J Clin Oncol. 2017;8(3):241–8.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Rodriguez-Wallberg KA, Oktay K. Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer. Oncologist. 2012;17:1409–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Surbone A, Petrek JA. Childbearing issues in breast carcinoma survivors. Cancer. 1997;79:1271–8.

    Article  CAS  PubMed  Google Scholar 

  93. Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5:172ra21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  94. Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol. 1989;16:337–46.

    CAS  PubMed  Google Scholar 

  95. Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer. 1990;65:847–50.

    Article  CAS  PubMed  Google Scholar 

  96. Decanter C, Gligorov J. Oocyte/embryo cryopreservation before chemotherapy for breast cancer. Gynecol Obstet Fertil. 2011;39:501–3.

    Article  CAS  PubMed  Google Scholar 

  97. Shalom-Paz E, Almog B, Shehata F, Huang J, Holzer H, Chian RC, et al. Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification. Reprod Biomed Online. 2010;21:566–71.

    Article  PubMed  Google Scholar 

  98. Menon U, Harper J, Sharma A, Fraser L, Burnell M, ElMasry K, et al. Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod. 2007;22:1573–7.

    Article  CAS  PubMed  Google Scholar 

  99. Sagi M, Weinberg N, Eilat A, Aizenman E, Werner M, Girsh E, et al. Preimplantation genetic diagnosis for BRCA1/2 – a novel clinical experience. Prenat Diagn. 2009;29:508–13.

    Article  CAS  PubMed  Google Scholar 

  100. Wang CW, Hui EC. Ethical, legal and social implications of prenatal and preimplantation genetic testing for cancer susceptibility. Reprod Biomed Online. 2009;19(Suppl 2):23–33.

    Article  CAS  PubMed  Google Scholar 

  101. Cold S, Düring M, Ewertz M, Knoop A, Møller S. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer. 2005;93:627–32. [PMID: 16136052]. https://doi.org/10.1038/sj.bjc.6602734.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, Olivotto IA. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24:4888–94. [PMID: 17015884]. https://doi.org/10.1200/JCO.2005.01.6089.

    Article  PubMed  Google Scholar 

  103. Marrs RP, Greene J, Stone BA. Potential factors affecting embryo survival and clinical outcome with cryopreserved pronuclear human embryos. Am J Obstet Gynecol. 2004;190:1766–71. [PMID: 15284794]. https://doi.org/10.1016/j.ajog.2004.02.049.

    Article  PubMed  Google Scholar 

  104. Check JH, Katsoff B, Wilson C, Choe JK, Brasile D. Pregnancy outcome following fresh vs frozen embryo transfer into gestational carriers using a simplified slow freeze protocol. Clin Exp Obstet Gynecol. 2012;39:23–4.. [PMID: 22675949]

    CAS  PubMed  Google Scholar 

  105. Azim HA, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De MAL, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart MJ, Peccatori FA. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013;31:73–9. [PMID: 23169515]. https://doi.org/10.1200/JCO.2012.44.2285.

    Article  PubMed  Google Scholar 

  106. Oktay K, Rodriguez-Wallberg K, Munster P. Ovarian protection during adjuvant chemotherapy. N Engl J Med. 2015;372:2268–9. [PMID: 26039611]. https://doi.org/10.1056/NEJMc1504241#SA2.

    Article  CAS  PubMed  Google Scholar 

  107. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O, Fehm T, Rezai M, Mehta K, Loibl S. German Breast Group Investigators. Effect of luteinizing hormonereleasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29:2334–41. [PMID: 21537042]. https://doi.org/10.1200/JCO.2010.32.5704.

    Article  CAS  PubMed  Google Scholar 

  108. Oktay K, Bedoschi G. Appraising the biological evidence for and against the utility of GnRHa for preservation of fertility in patients with cancer. J Clin Oncol. 2016;34:2563–5. [PMID: 27217452]. https://doi.org/10.1200/JCO.2016.67.1693.

    Article  CAS  PubMed  Google Scholar 

  109. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, Mulder J, Green D, Nicholson HS, Yasui Y, Robison LL. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Canc r Inst. 2006;98:890–6. [PMID: 16818852]. https://doi.org/10.1093/jnci/djj243.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Istanbul University School of Medicine, Istanbul, Turkey

    Ercan Bastu & Faruk Buyru

Authors
  1. Ercan Bastu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Faruk Buyru
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oncology Institute, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    Adnan Aydiner

  2. Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    Abdullah Igci

  3. Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Magee-Women’s Hospital of UPMC, Pittsburgh, PA, USA

    Atilla Soran

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bastu, E., Buyru, F. (2019). Reproductive Issues in Breast Cancer. In: Aydiner, A., Igci, A., Soran, A. (eds) Breast Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-16792-9_48

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16792-9_48

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16791-2

  • Online ISBN: 978-3-030-16792-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation